Advertisement Fidelity
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 32
Posts 26,670
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Top Equities Stories of the Day
Barrick Gold and Newmont Mining were in advanced talks this week over a deal that would have combined the world's two largest gold producers, according to people familiar with the matter.
Client Balances at Morgan Stanley Wealth Management Near Merrill Lynch
Citi Picks Dewilde to Lead Asia Markets and Investor Services Business
U.S. Hot Stocks: Hot Stocks to Watch
Fast-Rising Costs Erode Google's Profits -- 3rd Update
IBM's Profit Slides As Hardware Sales Keep Falling
SanDisk, Weibo Gains Pace Tech Stocks
European Stocks Turn Higher, But Rémy, Diageo Lag
U.S. Stocks Gain Broadly
Yahoo CEO Mayer's Compensation Falls
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 67036 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist